Drugs / S-4321
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07455578 | Jun 2026 → Sep 2027 expected | atopic eczema, cutaneous lupus erythematosus, psoriasis, psoriatic arthritis | Seismic Therapeutic AU Pty Ltd | Recruiting | No outcome recorded |
| Phase 1 | NCT06877611 | Apr 2025 → Apr 2026 overdue | — | Seismic Therapeutic AU Pty Ltd | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | S-4321 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07455578 ↗ |
| Route | Intravenous | “S-4321 via subcutaneous or intravenous administration” NCT06877611 ↗ |
| Route | Subcutaneous | “S-4321 via subcutaneous or intravenous administration” NCT06877611 ↗ |